Pancreatic β-cells are finely tuned to secrete insulin so that plasma glucose levels are
maintained within a narrow physiological range (3.5-5.5 mmol/L). Hyperinsulinaemic …

Known treatments of type 2 diabetes mellitus have limitations such as weight gain, and
hypoglycaemias. A new perspective is the use of incretin hormones and incretin enhancers …

Peripheral administration of glucagon-like peptide (GLP)-1 reduces food intake in animals
and humans, but the sites and mechanism of this effect and its physiological significance are …

Proglucagon is cleaved to glucagon by prohormone convertase 2 (PC2) in pancreatic a-
cells, but is cleaved to glucagon-like peptide-1 (GLP-1) by PC1 in intestinal L-cells. The aim …

The calcium-regulated phosphatase calcineurin intersects with both calcium and cAMP-
mediated signaling pathways in the pancreatic β-cell. Pharmacologic calcineurin inhibition …

Aims/hypothesis Exendin-4 is a 39 amino acid agonist of the glucagon-like peptide receptor
and has been approved for treatment of type 2 diabetes. Many reports describe an …

The in vitro DPP-IV inhibitory activity of isolated peptides from of tuna cooking juice
hydrolyzed by Protease XXIII (PR) and orientase (OR) was determined. The results showed …

Various warm-and cold-water fish skins were used to prepare gelatin hydrolysates and
compare their in vitro dipeptidyl peptidase IV (DPP-IV) inhibitory activity. The DPP-IV …

Placental insufficiency is a primary cause of intrauterine growth restriction (IUGR). IUGR
increases the risk of developing type 2 diabetes mellitus (T2DM) throughout life, which …

We have recently demonstrated the existence of a neuromodulatory regulation of prolactin
secretion by the opioid system showing a paradoxical opioid-induced prolactin suppression …